Clinical trials: POAG
Open Angle Glaucoma, Eye Diseases
Effect of Repeated Low-Level Red-Light Therapy on Visual Field Damage in Primary Open-angle Glaucoma
The purpose of this study is to investigate the effect of repeated low-level red-light therapy on existing visual field damages in primary open-angle glaucoma patients.
- Trial name
- NCT05309811
- Testing
- RLRL therapy, Routine IOP-lowering medications
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Primary Open Angle Glaucoma
The Effects of an Antioxidant Formulation on Ocular Blood Flow
The objective is to evaluate the effects of an antioxidant formula versus placebo on ocular blood flow in a randomized double-blind, crossover design.
- Trial name
- NCT01930487
- Testing
- dietary supplement with antioxidants
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- ScienceBased Health
Glaucoma, Primary Open Angle Glaucoma (POAG)
Evaluation of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma
This study aims to evaluate the effects of BrudyGlauco, a nutritional supplement containing DHA (docosahexaenoic acid) and citicoline, on visual function in people with glaucoma.
- Conditions
- Glaucoma, Primary Open Angle Glaucoma (POAG), Neuroprotection
- Trial name
- BRUDYGLAUCO (NCT07322965)
- Testing
- BrudyGlauco
- Where
- 2 sites in Spain
- Volunteers
- 108 people
- Sponsor
- Institut Catala de Retina
Glaucoma and Ocular Hypertension
A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT
The purpose of this study is to investigate the safety and efficacy of up to three concentrations of DE-117 ophthalmic solution (Low Dose, Medium Dose, and High Dose) as monotherapy and as adjunctive therapy (DE-117 ophthalmic…
- Trial name
- NCT01654484
- Testing
- DE-117, 0.0015% tafluprost, DE-117 and 0.0015% tafluprost
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Santen Inc.
Glaucoma, Angle-Closure, Ocular Hypertension
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma
To demonstrate that the intraocular pressure(IOP)-lowering efficacy of Travoprost (0.004%) is equal or better than that of Latanoprost 0.005% in patients with chronic angle-closure glaucoma.
- Trial name
- NCT00051181
- Testing
- Travoprost (0.004%), Latanoprost (0.005%)
- Where
- 2 sites in United States, Australia
- Sponsor
- Alcon Research
Ocular Hypertension Glaucoma, POAG
Direct Selective Laser Trabeculoplasty (DSLT) for Patients With Glaucoma or Ocular Hypertension Previously Treated With SLT
This study looks at a new laser treatment for people with high eye pressure or a type of glaucoma called open-angle glaucoma. All patients in the study have already had a similar laser treatment before (called SLT).
- Trial name
- NCT07589270
- Testing
- DSLT
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- The New York Eye Surgery Center
Open-angle Glaucoma, Ocular Hypertension
Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension
To investigate the safety and efficacy of DE-112 in lowering intraocular pressure in subjects with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01279083
- Testing
- DE-112, DE-112 Vehicle Solution, Timolol Maleate Solution
- Where
- 2 sites in United States
- Volunteers
- 147 people
- Sponsor
- Santen Inc.
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
The purpose of this study is to evaluate the intraocular pressure (IOP) lowering efficacy and the safety and tolerability profile of trabodenoson ophthalmic formulation compared to timolol maleate ophthalmic solution 0.5% in…
- Trial name
- NCT01917383
- Testing
- Trabodenoson, Latanoprost, Timolol
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Inotek Pharmaceuticals Corporation
Glaucoma, Glaucoma, Open-Angle
XEN45 in the Treatment of Chinese Patients With Primary Open-angle Glaucoma
Glaucoma is the second most common blindness disease in the world, second only to cataracts. The current treatment of glaucoma is mainly to reduce intraocular pressure.At present, two commonly used surgical methods are…
- Conditions
- Glaucoma, Glaucoma, Open-Angle, Surgery
- Trial name
- NCT05130554
- Testing
- XEN45 gel stent implantation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Ocular Hypertension, Primary Open Angle Glaucoma
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
This is a phase 2, double masked, randomized, multi-center, parallel-group, 28-day study assessing the safety, tolerability and ocular hypotensive efficacy of AKB-9778 Ophthalmic Solution 4.0% administered once (AM) or twice (AM…
- Trial name
- NCT04405245
- Testing
- Latanoprost ophthalmic solution, AKB-9778 4%
- Where
- 21 sites in United States
- Volunteers
- 194 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Primary Open-angle Glaucoma
Multicenter Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Cataract Surgery
Evaluate the safety and efficacy of the Glaukos® Suprachoroidal Stent Model G3 in conjunction with cataract surgery, compared to cataract surgery only, in subjects with mild to moderate primary open-angle glaucoma.
- Trial name
- NCT01461278
- Testing
- iStent supra, Cataract surgery
- Where
- United States
- Volunteers
- 505 people
- Sponsor
- Glaukos Corporation
Open-Angle Glaucoma, Ocular Hypertension
Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
This is an observational study in patients with POAG or OHT that will collect data on the use of Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) in a routine clinical setting.
- Trial name
- NCT01568008
- Testing
- Bimatoprost 0.01% ophthalmic solution
- Where
- Belgium
- Volunteers
- 933 people
- Sponsor
- Allergan
Primary Open-angle Glaucoma, Ocular Hypertension
Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension
This is a study of the safety, tolerability, pharmacokinetics (measurement of drug levels in the blood), and intraocular pressure lowering effects of OPA-6566 ophthalmic solution in subjects with primary open-angle glaucoma or…
- Trial name
- NCT01410188
- Testing
- OPA-6566, Latanoprost
- Where
- 9 sites in United States
- Volunteers
- 160 people
- Sponsor
- Kubota Vision Inc.
Primary Open Angle Glaucoma
Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma
Glaucoma is the second leading cause of blindness among seniors in Canada. It is often associated with an elevated intraocular pressure (IOP), but its exact mechanism is still largely unknown.
- Trial name
- NCT01711177
- Testing
- travoprost
- Where
- Canada
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Université de Montréal
Open-Angle Glaucoma, Ocular Hypertension
Study of TRAVATAN in Subjects With Iris Pigmentation Changes
The purpose of this study was to monitor iris pigmentation changes over a 5-year period in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00047554
- Testing
- Travoprost, 0.004% ophthalmic solution
- Volunteers
- 336 people
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma, Myopia
Diagnostic Innovations in Glaucoma Study
The overarching goal of our research study is to evaluate changes in visual function and optic nerve topography (the structure of the back of the eye) in patients with glaucoma (increased susceptibility to pressure inside the eye…
- Trial name
- DIGS (NCT00221897)
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Primary Open Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose
Primary objective: The primary objective is to demonstrate the superiority of Monoprost® versus Lumigan® 0.01% and Lumigan® 0.03% Unit Dose in term of safety with respect to the assessment of conjunctival hyperaemia in the worse…
- Trial name
- NCT02017327
- Testing
- Monoprost, Lumigan 0.01%, Lumigan 0.03% Unit Dose
- Where
- France
- Volunteers
- 379 people
- Sponsor
- Laboratoires Thea
Ocular Hypertension, Primary Open-Angle Glaucoma
Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
This study has 2 parts. Part 1 will evaluate the safety and IOP effects of 6 formulations of AGN-210961 ophthalmic solution in the study eye and bimatoprost ophthalmic solution 0.03% in the fellow eye for 7 consecutive days.
- Trial name
- NCT01110499
- Testing
- AGN-210961 Formulation 1, AGN-210961 Formulation 2, AGN-210961 Formulation 3
- Where
- United States
- Volunteers
- 163 people
- Sponsor
- Allergan
Open-angle Glaucoma
Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost
Evaluation of the intraocular pressure (IOP) lowering effect of two iStent devices versus medical therapy in eyes of subjects with primary open-angle glaucoma, pseudoexfoliative glaucoma, or ocular hypertension naïve to medical…
- Trial name
- NCT01443988
- Testing
- iStent, Travoprost
- Where
- Armenia
- Volunteers
- 101 people
- Sponsor
- Glaukos Corporation
Primary Open-Angle Glaucoma, Primary Angle-Closure Glaucoma
Combined Phacoemulsification-Goniotomy in Primary Open-Angle and Primary Angle-Closure Glaucoma
This study evaluates whether combining cataract surgery (phacoemulsification) with incisional goniotomy effectively lowers intraocular pressure (IOP) and reduces the need for glaucoma medications in patients with coexisting…
- Conditions
- Primary Open-Angle Glaucoma, Primary Angle-Closure Glaucoma, Cataract
- Trial name
- NCT07821827
- Testing
- Combined Phacoemulsification and Goniotomy
- Volunteers
- 70 people
- Sponsor
- Assiut University